CAJ | 학술논문

目的：通过分析13例服用索拉非尼患者的生存期，探讨索拉非尼在延长晚期肾癌患者的总体生存期的临床治疗经验。方法回顾2004年1月至2013年10月我院晚期转移性肾癌患者13例的临床资料，男9例，女4例；年龄37～75岁，中位年龄53岁。13例患者中保守治疗2例，行肾癌根治术11例。用药方法为连续口服索拉非尼400mg或600mg，2次／d。观察患者的总体生存期、中位生存期、中位无疾病进展时间和不良反应发生率。结果13例服药患者中，肺肿瘤转移灶体积缩小≥30％4例（30．7％），＜30％5例（38．5％），肺转移灶缩小3个月后开始增大，但未超过20％或出现新病灶4例（30．7％）。常见不良反应包括手足皮肤病变、腹泻、高血压、乏力，对症治疗后大多数可缓解，无需停药。结论索拉非尼能够抑制晚期肾癌的进展，延长患者的总体生存期。
목적：통과분석13례복용색랍비니환자적생존기，탐토색랍비니재연장만기신암환자적총체생존기적림상치료경험。방법회고2004년1월지2013년10월아원만기전이성신암환자13례적림상자료，남9례，녀4례；년령37～75세，중위년령53세。13례환자중보수치료2례，행신암근치술11례。용약방법위련속구복색랍비니400mg혹600mg，2차／d。관찰환자적총체생존기、중위생존기、중위무질병진전시간화불량반응발생솔。결과13례복약환자중，폐종류전이조체적축소≥30％4례（30．7％），＜30％5례（38．5％），폐전이조축소3개월후개시증대，단미초과20％혹출현신병조4례（30．7％）。상견불량반응포괄수족피부병변、복사、고혈압、핍력，대증치료후대다수가완해，무수정약。결론색랍비니능구억제만기신암적진전，연장환자적총체생존기。
Objective To explore the clinical treatment experience of Sorafenib in prolonging the overall survival of pa‐tients with advanced kidney cancer .Methods Clinical data of 13 cases of advanced kidney cancer treated during Jan .2004 and Oct .2013 were retrospectively reviewed .The patients included 9 males and 4 females ,aged 37‐75 years ,the median age being 53 years .Of all patients ,2 received conservative treatment and 11 underwent radical treatment .Sorafenib 400 mg or 600 mg was given twice per day .The patients'overall survival ,median survival period ,median time of disease progression and inci‐dence of adverse reactions were observed .Results Of all 13 cases ,4 (30 .7% ) had lung tumor metastases shrinkage ≥ 30% , 5 (38 .5) had lung metastases shrinkage <30% .In another 4 cases (30 .7% ) ,lung metastases began to enlarge after 3 months , but the enlargement was <20% and no new lesions occurred .Common adverse reactions included foot and skin lesions ,diar‐rhea ,high blood pressure and fatigue ,most of which could alleviate after symptomatic treatment .There was no need not stop Sorafenib medication .Conclusion Sorafenib can inhibit the progress of advanced kidney cancer and prolong the overall sur‐vival of patients .